Prevention of Radiation-Induced Breast Cancer by Amifostine
Abstract
Exposure to ionizing radiation at doses used in cancer radiotherapy and diagnostic radiology can increase breast cancer risk in women less than 45 years of age. Amifostine is a currently used cytoprotective agent. In addition to its cytoprotective effect, amifostine has been reported to inhibit radiation-induced mutagenesis in cultured cells and to protect against radiation-induced tumorigenesis in rodent model systems. This project is a pre-clinical study designed to determine if amifostine might be effective in preventing breast cancer initiation by medical exposures to ionizing radiation. The experiments will determine if amifostine is protective in a murine model of breast cancer initiation and, if so, determine the optimum dose, route and timing for its administration. The first year's objective was to test a high dose of amifostine administered I.P. prior to irradiation for reduction of ductal dysplasia in an outgrowth assay. In the first year 412 mammary fat pads were transplanted with mammary epithelial cells from irradiated donors. Of these, 306 have been harvested and examined as whole mounts. No dysplasias have been seen, but due to the low outgrowth frequency no conclusions can be drawn yet on the effectiveness of amifostine.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2003
- Accession Number
- ADA418558
Entities
People
- Michael M. Weil
Organizations
- The University of Texas MD Anderson Cancer Center